Oculis
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- -
- Employees
- 36
- Market Cap
- $553.1M
- Introduction
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
Oculis Holding's OCS-05 improves vision function in phase II
Oculis Holding AG's OCS-05 shows promise in treating acute optic neuritis, improving vision. FDA issues first AI guidance for drug development. Interest grows in PH treatment. Tanvex faces FDA hurdles for Herceptin biosimilar. South Korea boosts health and biomedical R&D funding. HHS proposes stricter HIPAA security measures.
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05
Oculis Holding AG reported positive phase II trial results for OCS-05, showing neuroprotection and vision improvement in acute optic neuritis patients, when combined with standard steroid treatment, compared to steroids alone.
Oculis releases positive topline results from phase 2 ACUITY trial evaluating OCS-05 in acute optic neuritis
Oculis reported positive phase 2 ACUITY trial results for OCS-05 in acute optic neuritis, showing neuroprotective benefits and improved visual function. The trial involved 36 patients, with OCS-05 demonstrating safety and efficacy, including improvements in retinal structure and vision. OCS-05 has FDA and EMA orphan drug designation.
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary and Secondary Endpoints
Oculis Holding AG announced positive Phase 2 ACUITY trial results for OCS-05, a neuroprotective candidate for acute optic neuritis, meeting safety and efficacy endpoints. The trial showed OCS-05 improved visual function and retinal structure, with no significant safety concerns. OCS-05 has received orphan drug designation from FDA and EMA.
Oculis' OCS-05 Shows Breakthrough 43% Vision Improvement in Phase 2 Optic Neuritis Trial
Oculis reported positive Phase 2 ACUITY trial results for OCS-05 in acute optic neuritis, meeting safety and efficacy endpoints. Key outcomes: 43% GCIPL thickness improvement, 28-30% RNFL thickness improvement, and ~18 letters visual function improvement. No serious adverse events. FDA granted orphan drug designation, IND cleared. Cash: ~$105-110M.
Oculis Hits New 52-Week High – Here’s What Happened
Oculis Holding AG's stock reached a 52-week high, trading at $17.57 with a volume of 58,391 shares. HC Wainwright reiterated a 'buy' rating with a $30 target. The company, focused on ophthalmic disease treatments, has a market cap of $711.25M and is advancing OCS-01, OCS-02, and OCS-05 through clinical trials.
Oculis price target raised to $31 from $23 at BofA
BofA increased Oculis's (OCS) price target to $31 from $23, maintaining a Buy rating, following positive Phase 2 ACUITY trial results for OCS-05 in treating AON. The trial demonstrated safety and promising efficacy, leading to plans for regulatory discussions and a pivotal trial. BofA also raised the AON market contribution estimate to $330M from $10M.
OCS-05 for Acute Optic Neuritis Achieves Key Endpoints in Phase 2 ACUITY Trial
OCS-05, a neuroprotective therapy for acute optic neuritis, showed safety and efficacy in the Phase 2 ACUITY trial, improving visual function and retinal structure without serious adverse events. It offers hope for treating this rare condition, potentially expanding to other neuro-ophthalmic indications.
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis
OCS-05, a neuroprotective therapy, showed positive safety and efficacy in the Phase 2 ACUITY trial for acute optic neuritis, achieving significant improvements in retinal thickness and visual function. It received FDA IND clearance, enabling U.S. clinical development. Oculis plans further studies and explores its potential in other neuro-ophthalmic conditions.
© Copyright 2025. All Rights Reserved by MedPath